MA34489B1 - Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire - Google Patents

Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire

Info

Publication number
MA34489B1
MA34489B1 MA35698A MA35698A MA34489B1 MA 34489 B1 MA34489 B1 MA 34489B1 MA 35698 A MA35698 A MA 35698A MA 35698 A MA35698 A MA 35698A MA 34489 B1 MA34489 B1 MA 34489B1
Authority
MA
Morocco
Prior art keywords
glaucoma
treatment
receptor
ocular hypertension
adenosine agonists
Prior art date
Application number
MA35698A
Other languages
English (en)
Inventor
Juergen Klar
Degenfeld Georges Von
Hans-Georg Lerchen
Barbara Albrecht-Kuepper
Andreas Knorr
Peter Sandner
Daniel Meibom
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34489B1 publication Critical patent/MA34489B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'agonistes sélectifs du récepteur A1 à l'adénosine, en particulier de dicyanopyridines de formule (I), pour le traitement et/ou la prophylaxie du glaucome et de l'hypertension oculaire ainsi que leur utilisation pour la production d'un médicament destiné au traitement et/ou à la prophylaxie du glaucome et de l'hypertension oculaire.
MA35698A 2010-09-02 2011-08-29 Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire MA34489B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10175151 2010-09-02
PCT/EP2011/064829 WO2012028585A1 (fr) 2010-09-02 2011-08-29 Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire

Publications (1)

Publication Number Publication Date
MA34489B1 true MA34489B1 (fr) 2013-08-01

Family

ID=44582992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35698A MA34489B1 (fr) 2010-09-02 2011-08-29 Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire

Country Status (30)

Country Link
US (3) US20120058983A1 (fr)
EP (1) EP2611415B1 (fr)
JP (1) JP5875585B2 (fr)
KR (1) KR20140091457A (fr)
CN (1) CN103249400B (fr)
AP (1) AP3413A (fr)
AU (1) AU2011298430B2 (fr)
BR (1) BR112013005224A2 (fr)
CA (1) CA2809700A1 (fr)
CL (2) CL2013000599A1 (fr)
CR (1) CR20130094A (fr)
CY (1) CY1117458T1 (fr)
DK (1) DK2611415T3 (fr)
EA (1) EA028411B1 (fr)
ES (1) ES2570659T3 (fr)
HK (1) HK1188138A1 (fr)
HR (1) HRP20160532T1 (fr)
HU (1) HUE027295T2 (fr)
MA (1) MA34489B1 (fr)
MX (1) MX2013002396A (fr)
MY (1) MY160383A (fr)
NZ (1) NZ607624A (fr)
PL (1) PL2611415T3 (fr)
RS (1) RS54743B1 (fr)
SG (1) SG187974A1 (fr)
SI (1) SI2611415T1 (fr)
TW (1) TWI516266B (fr)
UA (1) UA111947C2 (fr)
WO (1) WO2012028585A1 (fr)
ZA (1) ZA201302340B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2807178T1 (sl) 2012-01-26 2017-09-29 Inotek Pharmaceuticals Corporation Anhidridni polimorf (2R,3S,4R,5R)-5-(6-(ciklofentilamino)-9H-purin-9-il)-3,4-dihidroksite- trahidrofuran-2-il))metil nitrat in postopki njegove priprave
WO2015089105A1 (fr) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
JP2016539986A (ja) * 2013-12-12 2016-12-22 バイエル ファーマ アクチエンゲゼルシャフト 腎疾患に対する薬剤としてのアデノシンａ１アゴニスト
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
CA2984984A1 (fr) * 2015-05-06 2016-12-01 Bayer Pharma Aktiengesellschaft Procede de preparation de monohydrochlorure de 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyan-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l- alaninate
WO2017137528A1 (fr) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Agoniste du récepteur a1 de l'adénosine pour utilisation dans le traitement de l'état de mal épileptique
CN112545983A (zh) * 2020-12-18 2021-03-26 合肥中龙神力动物药业有限公司 一种复方硫酸新霉素滴眼液及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052510A (en) 1974-12-18 1977-10-04 Sandoz, Inc. 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (fr) 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
DE4334919A1 (de) * 1993-10-13 1995-04-20 Liedtke Pharmed Gmbh Grenzwertig wirksame Arzneiformen mit Betablockern
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
DE4430638A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
CA2241567A1 (fr) 1996-01-17 1997-07-24 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
ATE548351T1 (de) 1996-01-29 2012-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten
JPH10324687A (ja) 1997-02-19 1998-12-08 Nippon Soda Co Ltd ピロール化合物、製法および農園芸用殺菌剤
WO1998054139A1 (fr) 1997-05-30 1998-12-03 Basf Aktiengesellschaft Procede de fabrication de thiopyridines substituees
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
HUP0300029A2 (en) 2000-02-25 2003-05-28 Hoffmann La Roche Adenosine receptor modulators, pharmaceutical compositions containing them and their use
WO2002006237A1 (fr) 2000-07-18 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Medicament comprenant un derive de dicyanopyridine
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
EP1341772A2 (fr) 2000-12-11 2003-09-10 E. I. du Pont de Nemours and Company Quinazolinones et pyridinylpyrimidinones pour la regulation de nuisibles invertebres
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja) 2001-12-20 2003-07-03 Yamanouchi Pharmaceut Co Ltd ２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
WO2003091246A1 (fr) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1388342A1 (fr) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Dérivés de cycloalkenylamine condensé avec un hététoaryle et acylé et leur utilisation comme produits pharmaceutiques
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
MXPA05006367A (es) 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004275719B2 (en) 2003-09-23 2010-08-19 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
BRPI0512514A (pt) 2004-06-25 2008-03-11 Taisho Pharmaceutical Co Ltd composto, antagonista para receptores de crf, e, uso de um composto
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
WO2006034446A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
EP1863482A1 (fr) 2005-03-24 2007-12-12 Bayer HealthCare AG Utilisation de 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines substituees pour traiter les lesions de reperfusion et les dommages de reperfusion
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
AU2007246172A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors 3
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007036075A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
EP2297104B1 (fr) 2008-05-29 2013-08-07 Bayer Intellectual Property GmbH Dicyanopyridines substituées par du 2-alcoxy et leur utilisation
DE102008062566A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102008062561A1 (de) * 2008-12-16 2010-06-24 Maxon Motor Ag Bausatz für einen Elektromotor mit einem Drehwinkelgeber
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
NZ596428A (en) * 2009-05-01 2014-03-28 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans

Also Published As

Publication number Publication date
WO2012028585A1 (fr) 2012-03-08
PL2611415T3 (pl) 2016-08-31
DK2611415T3 (en) 2016-05-23
AU2011298430A1 (en) 2013-03-21
UA111947C2 (uk) 2016-07-11
CA2809700A1 (fr) 2012-03-08
JP2013536819A (ja) 2013-09-26
CL2016001164A1 (es) 2016-12-23
HK1188138A1 (en) 2014-04-25
HRP20160532T1 (hr) 2016-06-17
CY1117458T1 (el) 2017-04-26
BR112013005224A2 (pt) 2016-05-03
MX2013002396A (es) 2013-04-03
TW201212926A (en) 2012-04-01
ZA201302340B (en) 2015-11-25
EA028411B1 (ru) 2017-11-30
RS54743B1 (sr) 2016-10-31
AP3413A (en) 2015-09-30
US20150306084A1 (en) 2015-10-29
SG187974A1 (en) 2013-04-30
CN103249400A (zh) 2013-08-14
US9040566B2 (en) 2015-05-26
TWI516266B (zh) 2016-01-11
AU2011298430B2 (en) 2015-02-26
CN103249400B (zh) 2015-04-22
MY160383A (en) 2017-03-15
SI2611415T1 (sl) 2016-06-30
US20130210797A1 (en) 2013-08-15
EA201300310A1 (ru) 2013-08-30
CR20130094A (es) 2013-07-01
EP2611415B1 (fr) 2016-02-24
HUE027295T2 (en) 2016-10-28
KR20140091457A (ko) 2014-07-21
JP5875585B2 (ja) 2016-03-02
US20120058983A1 (en) 2012-03-08
ES2570659T3 (es) 2016-05-19
EP2611415A1 (fr) 2013-07-10
AP2013006753A0 (en) 2013-02-28
CL2013000599A1 (es) 2013-08-09
NZ607624A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
MA42376B1 (fr) Dérivés d'oxopyridine substitués
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA33492B1 (fr) Inhibiteurs de bace
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA38365A1 (fr) Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
MA31918B1 (fr) Agents et épitopes de liaison à wise
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA38147A1 (fr) Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MY172303A (en) Compositions and methods of use of phorbol esters
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA34377B1 (fr) Composé de pipéridinyle en tant que modulateur de l'activité des récepteurs des chimiokines
MA45504A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives